Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012567 | 0.84 | NOS3 (0.38) | CHRNB4CHRNA3CHEK2PRKCZ | |
| SCHEMBL4790009 | 0.80 | CHRNA1 (0.40) | MKNK1CHRNB4CHRNA3SOS1P2RY12 | |
| SCHEMBL420438 | 0.75 | NOS3 (0.46) | — | |
| SCHEMBL4282777 | 0.72 | IRAK4 (0.39) | CHEK2PRKCZ | |
| SCHEMBL4292530 | 0.72 | NOS3 (0.39) | CHRNB4CHRNA3CHEK2PRKCZ | |
| SCHEMBL4018111 | 0.70 | NOS1 (0.44) | CHRNB4CHRNA3 | |
| SCHEMBL3404577 | 0.70 | CHRNB4 (0.39) | CHRNB4CHRNA3CHEK2PRKCZ | |
| SCHEMBL4292393 | 0.69 | NOS3 (0.40) | CHRNB4CHRNA3CHEK2PRKCZ | |
| SCHEMBL11455784 | 0.66 | CHRNB4 (0.52) | CHRNB4CHRNA3 | |
| SCHEMBL6610218 | 0.66 | LTA4H (0.50) | CHEK2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009158646-A1 | THERAPEUTIC COMPUNDS AND RELATED METHODS OF USE | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |